Division of Thoracic Surgery, Department of Cardiothoracic Surgery, New York University Langone Health, New York, NY.
Division of Thoracic Surgery, Department of Cardiothoracic Surgery, New York University Langone Health, New York, NY.
J Thorac Cardiovasc Surg. 2021 Dec;162(6):1654-1664. doi: 10.1016/j.jtcvs.2021.01.069. Epub 2021 Jan 30.
As the Coronavirus Disease 2019 pandemic continues, appropriate management of thoracic complications from Coronavirus Disease 2019 needs to be determined. Our objective is to evaluate which complications occurring in patients with Coronavirus Disease 2019 require thoracic surgery and to report the early outcomes.
This study is a single-institution retrospective case series at New York University Langone Health Manhattan campus evaluating patients with confirmed Coronavirus Disease 2019 infection who were hospitalized and required thoracic surgery from March 13 to July 18, 2020.
From March 13 to August 8, 2020, 1954 patients were admitted to New York University Langone Health for Coronavirus Disease 2019. Of these patients, 13 (0.7%) required thoracic surgery. Two patients (15%) required surgery for complicated pneumothoraces, 5 patients (38%) underwent pneumatocele resection, 1 patient (8%) had an empyema requiring decortication, and 5 patients (38%) developed a hemothorax that required surgery. Three patients (23%) died after surgery, 9 patients (69%) were discharged, and 1 patient (8%) remains in the hospital. No healthcare providers were positive for Coronavirus Disease 2019 after the surgeries.
Given the 77% survival, with a majority of patients already discharged from the hospital, thoracic surgery is feasible for the small percent of patients hospitalized with Coronavirus Disease 2019 who underwent surgery for complex pneumothorax, pneumatocele, empyema, or hemothorax. Our experience also supports the safety of surgical intervention for healthcare providers who operate on patients with Coronavirus Disease 2019.
随着 2019 年冠状病毒病(COVID-19)大流行的持续,需要确定 COVID-19 引起的胸部并发症的适当处理方法。我们的目的是评估 COVID-19 患者出现哪些并发症需要进行开胸手术,并报告早期结果。
本研究为纽约大学朗格尼健康曼哈顿校区的单机构回顾性病例系列研究,评估了 2020 年 3 月 13 日至 7 月 18 日期间因 COVID-19 感染住院并需要开胸手术的患者。
从 2020 年 3 月 13 日至 8 月 8 日,1954 名患者因 COVID-19 入住纽约大学朗格尼健康医院。这些患者中有 13 例(0.7%)需要开胸手术。2 例(15%)患者因复杂气胸而行手术,5 例(38%)患者行肺大疱切除术,1 例(8%)患者因脓胸而行剥脱术,5 例(38%)患者因血胸而行手术。3 例(23%)患者术后死亡,9 例(69%)患者出院,1 例(8%)患者仍在住院治疗。手术后没有医护人员检测出 COVID-19 阳性。
考虑到 77%的生存率,大多数患者已经出院,对于因复杂气胸、肺大疱、脓胸或血胸而行手术的少数 COVID-19 住院患者,开胸手术是可行的。我们的经验还支持对 COVID-19 患者进行手术干预的医护人员的安全性。